◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ALNY

Alnylam Pharmaceuticals Inc (ALNY) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

Alnylam Pharmaceuticals Inc (ALNY) operates in the BIOTECHNOLOGY industry and is headquartered in Cambridge, United States with about 2,500 employees. Its market capitalization is roughly $32 billion. In the fiscal year ended 2025-12-31, ALNY reported $3.7B in revenue and $314M in net income.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Interactive charts & full statements → Open the ALNY valuation workbench →

ALNY Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$4.8B	$3.7B	$2.2B	$1.8B	$1.0B	$844M	$493M	$220M	$75M	$90M	$47M	$41M	$51M	$47M	$67M	$83M	$100M	$101M	$96M	$51M	$27M
Gross Profit	$3.8B	$3.0B	$1.9B	$1.5B	$869M	$704M	$415M	$195M	$73M	$90M	$47M	$41M	$51M	$47M	$67M	$83M	$100M	$101M	$96M	$51M	$27M
Gross Margin %	79.7%	81.8%	85.6%	83.0%	83.7%	83.4%	84.2%	88.6%	97.6%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	$1.0B	$502M	($177M)	($282M)	($785M)	($709M)	($828M)	($939M)	($815M)	($500M)	($425M)	($296M)	($405M)	($93M)	($129M)	($55M)	($44M)	($48M)	($28M)	($93M)	($40M)
Operating Margin %	20.8%	13.5%	-7.9%	-15.4%	-75.7%	-83.9%	-168.1%	-427.5%	-1087.6%	-556.2%	-900.3%	-720.3%	-801.0%	-197.0%	-194.0%	-66.2%	-44.0%	-47.9%	-28.9%	-183.1%	-146.7%
Net Income	$807M	$314M	($278M)	($440M)	($1.1B)	($853M)	($858M)	($886M)	($761M)	($491M)	($410M)	($290M)	($360M)	($89M)	($106M)	($58M)	($44M)	($48M)	($26M)	($85M)	($35M)
Net Margin %	16.8%	8.5%	-12.4%	-24.1%	-109.0%	-101.0%	-174.2%	-403.2%	-1016.6%	-546.0%	-869.6%	-705.8%	-712.8%	-189.2%	-158.9%	-69.7%	-43.5%	-47.3%	-27.3%	-167.9%	-128.5%
EBITDA	—	$631M	($179M)	($258M)	($927M)	($662M)	($736M)	($885M)	($754M)	($487M)	($409M)	($277M)	($172M)	($83M)	($52M)	($50M)	($38M)	($41M)	($19M)	($75M)	($36M)
Earnings Per Share (EPS)	$5.90	$2.33	$-2.18	$-3.52	$-9.30	$-7.20	$-7.46	$-8.11	$-7.57	$-5.42	$-4.79	$-3.45	$-4.85	$-1.45	$-2.11	$-1.36	$-1.04	$-1.14	$-0.64	$-2.21	$-1.09
Shares Outstanding (M)	—	135M	128M	125M	122M	118M	115M	109M	101M	91M	86M	84M	74M	62M	50M	42M	42M	42M	41M	39M	32M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALNY Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$1.3B	$1.2B	$1.1B	$1.2B	$774M	$594M	$593M	$501M	$660M
Gross Profit	$992M	$956M	$829M	$1.1B	$631M	$523M	$490M	$415M	$591M
Gross Margin %	76.8%	81.9%	75.6%	84.2%	81.5%	88.0%	82.7%	82.8%	89.6%
Operating Income (EBIT)	$231M	$269M	$132M	$368M	($16M)	$18M	($105M)	($77M)	$49M
Operating Margin %	17.9%	23.0%	12.0%	29.5%	-2.1%	3.0%	-17.7%	-15.3%	7.4%
Net Income	$164M	$206M	$186M	$251M	($66M)	($57M)	($84M)	($112M)	($17M)
Net Margin %	12.7%	17.6%	17.0%	20.1%	-8.6%	-9.7%	-14.1%	-22.3%	-2.6%
EBITDA	—	$304M	$304M	$297M	$19M	$11M	($141M)	($60M)	$37M
Earnings Per Share (EPS)	$1.21	$1.49	$1.37	$1.83	$-0.51	$-0.44	$-0.65	$-0.87	$-0.13
Shares Outstanding (M)	—	138M	136M	137M	130M	130M	129M	129M	127M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALNY Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$887M	$524M	($8M)	$104M	($541M)	($642M)	($615M)	($278M)	($563M)	($383M)	($308M)	($189M)	($166M)	($69M)	($116M)	($87M)	($84M)	($72M)	$65M	$197M	($25M)
Capital Expenditures (CapEx)	$92M	$59M	$34M	$62M	$72M	$76M	$70M	$140M	$127M	$104M	$65M	$13M	$9M	$4M	$8M	$1M	$5M	$5M	$11M	$8M	$5M
Free Cash Flow (FCF)	$794M	$465M	($43M)	$42M	($613M)	($718M)	($685M)	($419M)	($690M)	($487M)	($372M)	($202M)	($175M)	($73M)	($124M)	($88M)	($89M)	($77M)	$55M	$189M	($30M)
FCF Margin %	16.5%	12.5%	-1.9%	2.3%	-59.1%	-85.0%	-139.1%	-190.5%	-920.5%	-541.6%	-789.4%	-491.7%	-345.3%	-154.1%	-185.8%	-106.8%	-89.0%	-76.7%	56.9%	370.8%	-110.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALNY Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$327M	$71M	$164M	$325M	$154M	($118M)	($95M)	$44M	$124M
Capital Expenditures (CapEx)	$35M	$22M	$23M	$12M	$14M	$9M	$9M	$4M	$8M
Free Cash Flow (FCF)	$292M	$49M	$140M	$313M	$139M	($127M)	($104M)	$40M	$116M
FCF Margin %	22.6%	4.2%	12.8%	25.1%	18.0%	-21.4%	-17.5%	7.9%	17.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALNY Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$5.6B	$5.0B	$4.2B	$3.8B	$3.5B	$3.6B	$3.4B	$2.4B	$1.6B	$2.0B	$1.3B	$1.4B	$1.1B	$421M	$288M	$282M	$393M	$481M	$555M	$494M	$240M
Cash & Cash Equivalents	$1.7B	$1.7B	$966M	$813M	$866M	$820M	$497M	$547M	$420M	$645M	$194M	$181M	$75M	$53M	$51M	$70M	$75M	$137M	$192M	$105M	$128M
Total Liabilities	$4.2B	$4.2B	$4.2B	$4.1B	$3.7B	$3.1B	$2.4B	$956M	$273M	$228M	$343M	$122M	$143M	$150M	$153M	$164M	$235M	$303M	$353M	$295M	$39M
Total Debt (Short + Long-Term)	$1.3B	$1.1B	$1.2B	$1.1B	$1.1B	$716M	$228M	$28M	$93M	$41M	$161M	$7M	$5M	$3M	$4M	$63M	$11M	$4M	$6M	$5M	$9M
Total Shareholders' Equity	$1.4B	$789M	$67M	($221M)	($158M)	$588M	$1.0B	$1.4B	$1.3B	$1.8B	$920M	$1.3B	$936M	$270M	$134M	$118M	$158M	$178M	$202M	$199M	$201M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALNY viewer.

ALNY Metric Deep Dives

Other Companies in BIOTECHNOLOGY

ARGX · argenx NV ADR — $62 billion
RVMD · Revolution Medicines Inc — $41 billion
ONC · BeiGene, Ltd. — $40 billion
RPRX · Royalty Pharma Plc — $34 billion
ROIV · Roivant Sciences Ltd — $29 billion
INSM · Insmed Inc — $26 billion
BNTX · BioNTech SE — $24 billion
GMAB · Genmab AS — $21 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← ALNT All “A” companies ALO →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.